ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.691,32
0,05%
S&P 500
5.263,51
-0,82%
Dow Jones
39.058,30
-1,54%
Euro vs US Dollar
1,08087
-0,15%
Bitcoin
66.978,72
-3,07%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) News

ABUS

Arbutus Biopharma (ABUS)

Arbutus Biopharma Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ABUS
DatumZeitQuelleÜberschriftSymbolFirma
22/05/202412h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
22/05/202408h00GlobeNewswire Inc.Arbutus to Present Imdusiran Data at EASL Congress 2024NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202415h03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202415h03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
17/05/202415h00Business WireWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueNASDAQ:ABUSArbutus Biopharma Corporation
09/05/202414h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ABUSArbutus Biopharma Corporation
07/05/202413h30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413h30GlobeNewswire Inc.Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413h25GlobeNewswire Inc.Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024NASDAQ:ABUSArbutus Biopharma Corporation
18/04/202413h30GlobeNewswire Inc.Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/04/202414h30GlobeNewswire Inc.Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
08/03/202413h30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
05/03/202422h48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
29/02/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
29/02/202413h30GlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
15/02/202413h30GlobeNewswire Inc.Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
14/02/202422h38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
14/02/202416h48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
06/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
06/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
06/02/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
06/02/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
08/01/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
08/01/202413h30GlobeNewswire Inc.Arbutus Announces 2024 Corporate Objectives and Provides Financial UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/01/202422h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
21/11/202314h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABUSArbutus Biopharma Corporation
09/11/202322h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
08/11/202313h30GlobeNewswire Inc.Arbutus to Present at Jefferies London Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202322h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
07/11/202313h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
 Showing the most relevant articles for your search:NASDAQ:ABUS

Kürzlich von Ihnen besucht

EU
GSCDG
Euronext Global Sustaina...
BIT
P1X6O2
NLBNPIT1X6O2 20240621 1.25
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten